Clinical Trial Results:
A multicentre, open label Phase IIIb/IV study of subcutaneously administered efalizumab in the treatment of adult patients with moderate to severe chronic plaque psoriasis who have failed to respond to, or who have a contraindication to, or are intolerant of other systemic therapies including ciclosporine, methotrexate and PUVA.
Summary
|
|
EudraCT number |
2004-001236-23 |
Trial protocol |
HU FI CZ DK SE ES SK AT IE IT DE GB |
Global completion date |
30 Apr 2007
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
13 Nov 2016
|
First version publication date |
13 Nov 2016
|
Other versions |
|
Summary report(s) |
2004-001236-23_EudraCT Disclosure Synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.